Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis

Expert Reviews in Molecular Medicine

Volumn 10, Issue 29, 2008, Pages 1-18

  Villar, Cristina Cunha ^a   Dongari Bagtzoglou, Anna ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CYTOKINE; DECTIN 1; FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 8; LIPID A DERIVATIVE; MANNOSE RECEPTOR; NYSTATIN; OM 174; PYRROLE DERIVATIVE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE;

CANDIDA ALBICANS; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG USE; EFFECTOR CELL; EPITHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MONOTHERAPY; MOUTH MUCOSA; NEUTROPHIL; NONHUMAN; OROPHARYNX CANDIDIASIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RELAPSE; REVIEW;

CANDIDA ALBICANS;

EID: 54549089115     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399408000835     Document Type: Review

References (156)

1. Odds, F.C. (1988) Candida and candidiasis. Balliere Tindall, London
2. Scully, C., el Kabir, M. and Samaranayake, L.P (1994) Candida and oral candidiasis: A review. Crit Rev Oral Biol Med 5, 125-157
3. Rubin, R.H. (1993) Fungal and bacterial infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 12, S42-48
4. Ohmit, S.E. et al. (2003) Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 188, 118-127
5. Redding, S.W. et al. (1999) Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol 37, 3896-3900
6. Hermann, P. et al. (2005) Incidence of oropharyngeal candidosis in stem cell transplant (SCT) patients. Acta Microbiol Immunol Hung 52, 85-94
7. Penk, A. and Pittrow, L. (1999) Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. Mycoses 42 (Suppl. 2), 97-100
8. Neville, B.W. et al. (2002) Oral and Maxillofacial Pathology, 2nd edn. Saunders, Philadelphia
9. Anaissie, E.J. and Bodey, G.P. (1990) Fungal infections in patients with cancer. Pharmacotherapy 10, 164S-169S
10. Richet, H.M. et al. (1991) Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 13, 211-215
11. Samonis, G. and Bafaloukos, D. (1992) Fungal infections in cancer patients: An escalating problem. In Vivo 6, 183-193
12. Mukhopadhyay, S. et al. (2004) The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology 112, 521-530
13. Brown, G.D. et al. (2003) Dectin-1 mediates the biological effects of β-glucans. J Exp Med 197, 1119-1124
14. Forsyth, C.B., Plow, E.F. and Zhang, L. (1998) Interaction of the fungal pathogen Candida albicans with integrin CD11b/CD18: Recognition by the I domain is modulated by the lectin-like domain and the CD18 subunit. J Immunol 161, 6198-6205
15. Underhill, D.M. et al. (1999) The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401, 811-815
16. Takeda, K. et al. (2003) Toll-like receptors. Annu Rev Immunol 21, 335-376
17. Janeway, C.A. and Medzhitov, R. (2002) Innate immune recognition. Annu Rev Immunol 20, 197-216
18. Roeder, A. et al. (2004) Toll-like receptors and innate antifungal responses. Trends Microbiol 12, 44-49
19. Bellocchio, S. et al. (2004) The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol. 172, 3059-3069
20. Gozalbo, D. et al. (2004) Candida and candidiasis: The cell wall as a potential molecular target for antifungal therapy, Curr Drug Targets Infect Disord 4, 117-135
21. Marr, K.A. et al. (2003) Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun. 71, 5280-5286
22. Netea, M.G. et al. (2002) The role of Toll-like receptors in the defense against disseminated candidiasis. J Infect Dis 185, 1483-1489
23. Villamon, E. et al. (2004) Toll-like receptor-2 is essential in murine defenses against Candida albicans infections. Microbes Infect 6, 1-7
24. Netea, M.G. et al. (2004) Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 3712-3718
25. Murciano, C. et al. (2006) Toll-like receptor 4 defective mice carrying point or null mutations do not show increased susceptibility to Candida albicans in a model of hematogenously disseminated infection. Med Mycol 44, 149-157
26. Fidel, P.L., Jr. (2002) Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 40, 359-375
27. Romani, L. (1999) Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 2, 363-367
28. Fidel, P.L., Jr. (2002) Immunity to Candida. Oral Dis 8 (Suppl. 2), 69-75
29. Uehara, A., Sugawara, S. and Takada, H. (2002) Priming of human oral epithelial cells by interferon-gamma to secrete cytokines in response to lipopolysaccharides, lipoteichoic acids and peptidoglycans. J Med Microbiol 51, 626-634
30. Hayashi, E, Means, T.K. and Luster, A.D. (2003) Toll-like receptors stimulate human neutrophil function. Blood 102, 2660-2669
31. Cottalorda, A. et al. (2006) TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 36, 1684-1693
32. Mahanonda, R. and Pichyangkul, S. (2007) Toll-like receptors and their role in periodontal health and disease. Periodontol 2000 43, 41-55
33. Pivarcsi, A. et al. (2003) Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 15, 721-730
34. Weindl, G. et al. (2007) Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J Clin Invest 117, 3664-3672
35. Netea, M.G. et al. (2006) Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 116, 1642-1650
36. Marodi, L., Forehand, J.R. and Johnston, R.B., Jr. (1991) Mechanisms of host defense against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J Immunol 146, 2790-2794
37. Marodi, L., Korchak, H.M. and Johnston, R.B., Jr. (1991) Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 146, 2783-2789
38. Yamamoto, Y., Klein, T.W. and Friedman, H. (1997) Involvement of mannose receptor in cytokine interleukin-1beta (IL-1beta), IL-6, and granulocyte-macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1beta (MIP-1beta), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect Immun 65, 1077-1082
39. Romani, L. et al. (2004) The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida. albicans. Int Immunol 16, 149-161
40. Dobozy, A. et al. (1996) Mannose receptors are implicated in the Candida albicans killing activity of epidermal cells. Acta Microbiol Immunol Hung 43, 93-95
41. Szolnoky, G. et al. (2001) A mannose-binding receptor is expressed on human keratinocytes and mediates killing of Candida albicans. J Invest Dermatol 117, 205-213
42. Lee, S.J. et al. (2003) Normal host defense during systemic candidiasis in mannose receptor-deficient mice. Infect Immun 71, 437-445
43. Brown, G.D. (2006) Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6, 33-43
44. Brown, G.D. and Gordon, S. (2001) Immune recognition. A new receptor for beta-glucans. Nature 413, 36-37
45. Gantner, B.N., Simmons, R.M. and Underhill, D.M. (2005) Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments. EMBO J 24, 1277-1286
46. Dongari-Bagtzoglou, A. (2008) Pathogenesis of mucosal biofilm infections: Challenges and progress. Expert Rev Anti Infect Ther 6, 201-208
47. Gow, N.A. et al. (2007) Immune recognition of Candida albicans beta-glucan by dectin-1. J Infect Dis 196, 1565-1571
48. Suram, S. et al. (2006) Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor. J Biol Chem 281, 5506-5514
49. Kennedy, A.D. et al. (2007) Dectin-1 promotes fungicidal activity of human neutrophils. Eur J Immunol 37, 467-478
50. Rogers, N.C. et al. (2005) Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectim. Immunity 22, 507-517
51. Gantner, B.N. et al. (2003) Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197, 1107-1117
52. Taylor, P.R. et al. (2007) Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 8, 31-38
53. Saijo, S. et al. (2007) Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 8, 39-46
54. Cambi, A. et al. (2003) The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol 33, 532-538
55. Taylor, P.R. et al. (2004) The role of SIGNR1 and the beta-glucan receptor (dectin-1) in the nonopsonic recognition of yeast by specific macrophages. J Immunol 172, 1157-1162
56. O'Neill, L.A. et al. (2003) Mal and MyD88: Adapter proteins involved in signal transduction. by Toll-like receptors. J Endotoxin Res 9, 55-59
57. Villamon, E. et al. (2004) Myeloid differentiation factor 88 (MyD88) is required for murine resistance to Candida albicans and is critically involved in Candida-induced production of cytokines. Eur Cytokine Netw 15, 263-271
58. Netea, M.G. et al. (2006) Recognition of fungal pathogens by toll-like receptors. Curr Pharm Des 12, 4195-4201
59. Saville, S.P. et al. (2003) Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2, 1053-1060
60. Mathieson, R. and Dutta, S.K. (1983) Candida esophagitis. Dig Dis Sci 28, 365-370
61. Netea, M.G. et al. (2008) An integrated model of the recognition of Candida. albicans by the innate immune system. Nat Rev Microbiol 6, 67-78
62. van der Graaf, C.A. et al. (2005) Differential cytokine production and Toll-like receptor signaling pathways by Candida albicans, blastoconidia. and hyphae. Infect Immun 73, 7458-7464
63. Lilly, E.A. et al. (2004) Tissue-associated cytokine expression in HIV-positive persons with oropharyngeal candidiasis. J Infect Dis 190, 605-612
64. Dongari-Bagtzoglou, A. and Kashleva, H. (2003) Granulocyte-macrophage colony-stimulating factor responses of oral epithelial cells to Candida albicans. Oral Microbiol Immunol 18, 165-170
65. Li, L., Kashleva, H. and Dongari-Bagtzoglou, A. (2007) Cytotoxic and cytokine-inducing properties of Candida glabrata in single and mixed oral infection models. Microb Pathog 42, 138-147
66. Li, L. and Dongari-Bagtzoglou, A. (2007) Oral epithelium-Candida glabrata interactions in vitro. Oral Microbiol Immunol 22, 182-187
67. Djeu, J.Y. et al. (1988) Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol 141, 4047-4052
68. Djeu, J.Y., Serbousek, D. and Blanchard, D.K. (1990) Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood 76, 1405-1409
69. Marquis, M. et al. (2006) CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1. Infect Immun 74, 2382-2391
70. Romani, L. (2004) Immunity to fungal infections. Nat Rev Immunol 4, 1-23
71. Steele, C. et al. (1999) Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 37, 251-259
72. Steele, C. et al. (2000) Growth inhibition of Candida by human oral epithelial cells. J Infect Dis 182, 1479-1485
73. Fidel, P.L., Jr. et al. (1999) Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 67, 3135-3140
74. Farah, C.S. et al. (2001) T cells augment monocyte and neutrophil function in host resistance against oropharyngeal candidiasis. Infect Immun 69, 6110-6118
75. Marquis, M. et al. (2006) CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida. albicans in transgenic mice expressing human immunodeficiency virus type 1. Infect Immun 74, 2382-2391
76. Baggiolini, M., Walz, A. and Kunkel, S.L. (1989) Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84, 1045-1049
77. Casale, T.B. and Carolan, E.J. (1999) Combination of IL-8 plus TNF alpha induces additive neutrophil migration. Allergy Asthma Proc 20, 361-363
78. Dongari-Bagtzoglou, A., Villar, C.C. and Kashleva, H. (2005) Candida albicans-infected oral epithelial cells augment the anti-fungal activity of human neutrophils in vitro. Med Mycol 43, 545-549
79. Pereira, H.A. and Hosking, C.S. (1984) The role of complement and antibody in opsonization and intracellular killing of Candida albicans. Clin Exp Immunol 57, 307-317
80. Richardson, M.D. and Smith, H. (1981) Resistance of virulent and attenuated strains of Candida albicans to intracellular killing by human and mouse phagocytes. J Infect Dis 144, 557-564
81. Aratani, Y. et al. (2002) Critical role of myeloperoxidase and nicotinamide adenine dinucleotide phosphate-oxidase in high-burden systemic infection of mice with Candida albicans. J Infect Dis 185, 1833-1837
82. Diamond, R.D., Lyman, C.A. and Wysong, D.R. (1991) Disparate effects of interferon-gamma and tumor necrosis factor-alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro. J Clin Invest 87, 711-720
83. Le, J. and Vilcek, J. (1987) Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 56, 234-248
84. Tan, A.M. et al. (1995) Activation of the neutrophil bactericidal activity for nontypable Haemophilus influenzae by tumor necrosis factor and lymphotoxin. Pediatr Res 37, 155-159
85. Gadish, M. et al. (1991) Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leuk Res 15, 1175-1182
86. Schroder, J.M. and Christophers, E. (1986) Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 87, 53-58
87. Djeu, J.Y. et al. (1990) Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. J Immunol 144, 2205-2210
88. Steinbakk, M. et al. (1990) Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336, 763-765
89. Sohnle, P.G., Collins-Lech, C. and Wiessner, J.H. (1991) Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis 163, 187-192
90. Hurtrel, B. and Lagrange, P.H. (1981) Comparative effects of carrageenan on systemic candidiasis and listeriosis in mice. Clin Exp Immunol 44, 355-358
91. Jensen, J., Warner, T. and Balish, E. (1993) Resistance of SCID mice to Candida albicans administered intravenously or colonizing the gut: Role of polymorphonuclear leukocytes and macrophages. J Infect Dis 167, 912-919
92. Qian, Q. et al. (1994) Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol 152, 5000-5008
93. Vonk, A.G. et al. (2002) Phagocytosis and intracellular killing of Candida albicans blastoconidia by neutrophils and macrophages: A comparison of different microbiological test systems. J Microbiol Methods 49, 55-62
94. Netea, M.G., Kullberg, B.J. and Van der Meer, J.W. (2004) Proinflammatory cytokines in the treatment of bacterial and fungal infections. BioDrugs 18, 9-22
95. Wellington, M., Bliss, J.M. and Haidaris, C.G. (2003) Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment. Infect Immun 71, 7228-7231
96. Wellington, M., Dolan, K. and Haidaris, C.G. (2007) Monocyte responses to Candida albicans are enhanced by antibody in cooperation with antibody-independent pathogen recognition. FEMS Immunol Med Microbiol 51, 70-83
97. Beno, D.W., Stover, A.G. and Mathews, H.L. (1995) Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes. J Immunol 157, 5273-5281
98. Farah, C.S. et al. (2002) Primary role for CD4(+) T lymphocytes in recovery from oropharyngeal. candidiasis. Infect Immun 70, 724-731
99. Leigh, J.E., McNulty, K.M. and Fidel, P.L., Jr. (2006) Characterization of the immune status of CD8+ T cells in oral lesions of human immunodeficiency virus-infected persons with oropharyngeal Candidiasis. Clin Vaccine Immunol 13, 678-683
100. Deitch, E.A. et al. (1995) Caco-2 and IEC-18 intestinal epithelial cells exert bactericidal activity through an oxidant-dependent pathway. Shock 4, 345-350
101. Jones-Carson, J. et al. (1995) Gamma delta T cell-induced nitric oxide production enhances resistance to mucosal candidiasis. Nat Med 1, 552-557
102. Dunsche, A. et al. (2001) Expression profile of human defensins, and antimicrobial proteins in oral tissues. J Oral Pathol Med 30, 154-158
103. Dunsche, A. et al. (2002) The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci 110, 121-124
104. Harder, J. et al. (2001) Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276, 5707-5713
105. Liu, A. et al. (2002) Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Investig Dermatol 118, 275-281
106. Mathews, M. et al. (1999) Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun Infect Immun 67, 2740-2745
107. Schroder, J.M. and Harder, J. (1999) Human beta-defensin-2. Int J Biochem Cell Biol 31, 645-651
108. Feng, Z. et al. (2005) Human beta-defensins: Differential activity against candidal species and regulation by Candida albicans. J Dent Res 84, 445-450
109. Garcia, J.R. et al. (2001) Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 306, 257-264
110. Nomanbhoy, F. et al. (2002) Vaginal and oral epithelial cell anti-Candida activity. Infect Immun 70, 7081-7088
111. Steele, C. (2001) Potential role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells. Infect Immun 69, 7091-7099
112. Yano, J. et al. (2005) Oral and vaginal epithelial cell anti-Candida activity is acid labile and does not require live epithelial cells. Oral Microbiol Immunol 20, 199-205
113. Sakai, A. et al. (2007) Potential role of high molecular weight hyaluronan in the anti-Candida activity of human oral epithelial cells. Med Mycol 45, 73-79
114. Cantorna, M.T. and Balish, E. (1991) Role of CD4+ lymphocytes in resistance to mucosal candidiasis. Infect Immun 59, 2447-2455
115. Farah, C.S. and Ashman, R.B. (2005) Active and passive immunization against oral Candida albicans infection in a murine model. Oral Microbiol Immunol 20, 376-381
116. De Luca, A. et al. (2007) Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. J Immunol 179, 5999-6008
117. Montagnoli, C. et al. (2002) B7/CD28-dependent CD4 + CD25+ regulatory T cells are essential components of the memory-protective immunity to Candida albicans. J Immunol 169, 6298-6308
118. Sutmuller, R.P. et al. (2006) Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116, 485-494
119. Zelante, T. et al. (2007) IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37, 2695-2706
120. LeibundGut-Landmann, S. et al. (2007) Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 8, 630-638
121. Veldhoen, M. et al. (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189
122. Mangan, P.R. et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441, 231-234
123. Bettelli, E. et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238
124. Ivanov, S. et al. (2007) Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am J Respir Cell Mol Biol 36, 442-451
125. Aggarwal, S. et al. (2003) Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278, 1910-1914
126. Langrish, C.L. et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201, 233-240
127. Acosta-Rodriguez, E.V. et al. (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8, 639-646
128. Weaver, C.T. et al. (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25, 821-852
129. Huang, W. et al. (2004) Requirement of interleukin-17A for systemic anti-Candida albicans, host defense in mice. J Infect Dis 190, 624-631
130. Rogers, T.R. (2006) Antifungal drug resistance: Limited data, dramatic impact? Int J Antimicrob Agents 27 Suppl 1, 7-11
131. Schaller, M. et al. (2004) Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. Microbiology 150, 2807-2813
132. Tardif, F. et al. (2004) Involvement of interleukin-18 in the inflammatory response against oropharyngeal candidiasis. Med Sci Monit 10, 239-249
133. Ziege, S.U. et al. (2000) In vitro effects of interleukin-10, prednisolone, and GM-CSF on the non-specific immune function of human polymorphonuclear leucocytes and monocytes. Eur J Med Res 5, 369-374
134. Richardson, M.D., Brownlie, C.E. and Shankland, G.S. (1992) Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 30, 433-441
135. Kurt-Jones, E.A. et al. (2002) Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated mterleukm 8 responses in neutrophils. Blood 100, 1860-1868
136. Willment, J.A. et al. (2003) Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol 171, 4569-4573
137. van Eijk, M. et al. (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17, 1505-1512
138. Vazquez, J.A., Gupta, S. and Villanueva, A. (1998) Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis 17, 781-783
139. Vazquez, J.A., Flidalgo, J.A. and De Bono, S. (2000) Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: A pilot study. HIV Clin Trials 1, 23-29
140. Clemons, K.V. and Stevens, D.A. (2000) Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol 38, 213-219
141. Gallin, J.I. et al. (1995) Interferon-gamma in the management of infectious diseases. Ann Intern Med 123, 216-224
142. Murray, H.W. (1994) Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 97, 459-467
143. Torrico, F. et al. (1991) Endogenous IFN-gamma is required for resistance to acute Trypanosoma. cruzi infection in mice. J Immunol 146, 3626-3632
144. Bodasing, N. et al. (2002) Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother 50, 765-766
145. Ohta, H. et al. (2007) Regulation of Candida albicans morphogenesis by tumor necrosis factor-alpha and potential for treatment of oral candidiasis. In Vivo 21, 25-32
146. Gamble, J.R. et al. (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A 82, 8667-8671
147. Rice, P.J. et al. (2005) Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther 314, 1079-1086
148. Verstak, B., Hertzog, P. and Mansell, A. (2007) Toll-like receptor signalling and the clinical benefits that lie within. Inflamm. Res 56, 1-10
149. Garay, R.P. et al. (2007) Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help. Eur J Pharmacol. 563, 1-17
150. Re, F. and Strominger, J.L. (2004) IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines, that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol 173, 7548-7555
151. Namba, K. et al. (1997) Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. Vaccine 15, 405-413
152. Onier, N. et al. (1999) Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Int J Cancer 81, 755-760
153. Spellberg, B.J. et al. (2005) The anti-Candida albicans; vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 73, 6191-6193
154. Spellberg, B.J. et al. (2006) Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194, 256-260
155. Ibrahim, A.S. et al. (2006) The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun 74, 3039-3041
156. Ibrahim, A.S. et al. (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73, 999-1005